期刊文献+

基于药品不良反应监测系统的假冒伪劣医疗产品检测方法 被引量:4

Detection Methods of Substandard/Spurious/Falsely Labelled/Falsified and Counterfeit Medical Products Based on Adverse Drug Reaction Surveillance System
下载PDF
导出
摘要 目的假冒伪劣医疗产品不仅无法保证用药的有效性,还可能导致一些非预期的不良反应/事件,威胁公众的健康安全。当前对药品质量的检测除了依靠药物分析技术之外,还可以通过对药品上市后安全性数据进行挖掘,从而发现药品质量问题。方法通过查阅相关文献对几种不合格药品的检测方法,包括不相称测定分析,时间变化监测算法,聚类分析,药品不良事件聚集性信号预警系统进行介绍。结果上述几种检测方法都可以从一定角度发现药品质量问题。结论假冒伪劣医疗产品的检测方法尚无金标准,针对具体数据可采用不同方法进行分析,以期为药品监管工作提供方向和帮助。 Objective Substandard/Spurious/Falsely labelled/Falsified and Counterfeit (SSFFC) medical products can not only guarantee the effectiveness of drugs, but bring about unexpected adverse reactions/events, which may threaten public health. Detecting drug quality defects currently depends on the identification and early-warning of safety signals on post-marketing drugs besides pharmaceutical analysis. Methods In this paper, we introduce four detection methods by literature review, including Disproportional Filter, Temporal Change Detection Algorithm, Cluster Analysis and Early Warning System on Cluster Adverse Drug Events. Results To some extent, four methods above-mentioned can find drug quality defects. Conclusion So far, there are no golden standards in detection methods of SSFFC medical products. Take different methods to analyze data may be more effective, which may provide references for adverse drug reactions surveillance.
出处 《中国药物警戒》 2017年第8期489-492,共4页 Chinese Journal of Pharmacovigilance
基金 国家自然科学基金(81373105):贝叶斯倾向性评分方法研究及其在药品不良反应信号检测中的应用 上海市公共卫生重点学科(815GWZK0901):循证公共卫生与卫生经济学 上海市卫计委科研课题(201440379):药品不良反应信号检测中混杂因素控制的倾向性评分方法研究
关键词 劣质 假造 标签不当 伪造 假冒 医疗产品 检测方法 substandard spurious falsely labelled falsified counterfeit medical products dtectionmethods
  • 相关文献

参考文献8

二级参考文献63

  • 1陈易新.如何通过上市后药品安全性监测实现药品风险管理[J].中国药师,2007,10(4):375-377. 被引量:33
  • 2武志昂,毕开顺.刍议企业在药品上市后风险管理中的责任[J].中国药物警戒,2007,4(2):65-67. 被引量:12
  • 3Rawlins, M D. Spontaneous reporting of adverse drug reactions. I: the data[J]. Br J Clin Pharmacol, 1988,26(1): 1-5.
  • 4Rawlins, M D. Spontaneous reporting of adverse drug reactions. II: Uses[J]. Br J Clin Pharmacol, 1988,26(1): 7-11.
  • 5Finney, D J. The design and logic of a monitor of drug use [J].J Chronic Dis, 1965,18: 77-98.
  • 6Napke, E. Drug adverse reaction alerting program[J].Canad Pharm J, 1968,20:251-254.
  • 7Finney, D J Systematic signalling of adverse reactions to drugs[J]. Meth Inf Med, 1974,13: 1-10.
  • 8Napke, E. The Canadian drug adverse reaction reporting program [J]. Drug Inf J, 1975,9(2-3): 224-232.
  • 9Moore,N F Thiessard,B Begaud. The history of disproportionality measures (reporting odds ratio, proportional reporting rates) in spontaneous reporting of adverse drug reactions[J].Pharmacoepidemiol Drug Saf 2005,14(4): 285-286.
  • 10Hochberg, A M M Hauben, R K Pearson, et al. An evaluation of three signal-detection algorithms using a highly inclusive reference event database[J].Drug Saf,, 2009,32(6):509-525.

共引文献120

同被引文献18

引证文献4

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部